개 아토피 피부염 시장 : 세계 산업 분석, 규모, 점유율, 성장, 동향,예측(2025-2035년)

Canine Atopic Dermatitis Market - Scope of Report

TMR's report on the global canine atopic dermatitis market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2025 to 2035. The report provides revenue of the global canine atopic dermatitis market for the period 2019-2035, considering 2025 as the base year and 2035 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global canine atopic dermatitis market from 2025 to 2035.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the canine atopic dermatitis market.

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global canine atopic dermatitis market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global canine atopic dermatitis market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global canine atopic dermatitis market.

The report delves into the competitive landscape of the global canine atopic dermatitis market. Key players operating in the global canine atopic dermatitis market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global canine atopic dermatitis market profiled in this report.

Key Questions Answered in Global canine atopic dermatitis Market Report:

• What is the sales/revenue generated by canine atopic dermatitis across all regions during the forecast period?
• What are the opportunities in the global canine atopic dermatitis market?
• What are the major drivers, restraints, opportunities, and threats in the market?
• Which regional market is set to expand at the fastest CAGR during the forecast period?
• Which segment is expected to generate the highest revenue globally in 2035?
• Which segment is projected to expand at the highest CAGR during the forecast period?
• What are the market positions of different companies operating in the global market?

Canine Atopic Dermatitis Market - Research Objectives and Research Approach

The comprehensive report on the global canine atopic dermatitis market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global canine atopic dermatitis market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2035 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global canine atopic dermatitis market.

Table of Contents

1. Preface

• 1.1. Market Definition and Scope
• 1.2. Market Segmentation
• 1.3. Key Research Objectives
• 1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary : Global Canine Atopic Dermatitis Market

4. Market Overview

• 4.1. Introduction
  • 4.1.1. Segment Definition
  • 4.1.2. Industry Evolution / Developments
• 4.2. Overview
• 4.3. Market Dynamics
  • 4.3.1. Drivers
  • 4.3.2. Restraints
  • 4.3.3. Opportunities
• 4.4. Global Canine Atopic Dermatitis Market Analysis and Forecasts, 2020-2035
  • 4.4.1. Market Revenue Projections (US$ Bn)

5. Key Insights

• 5.1. Healthcare Expenditure Data across Key Countries
• 5.2. Brand and Pricing Analysis
• 5.3. Recent Advancements in Canine Atopic Dermatitis
• 5.4. PORTER's Five Forces Analysis
• 5.5. Regulatory Landscape across Key Regions / Countries
• 5.6. Go-to-Market Strategy for New Market Entrants across Key Regions / Countries
• 5.7. Supply Chain Analysis
• 5.8. Value Chain Analysis
• 5.9. PESTLE Analysis
• 5.10. Key Potential Customers

6. Global Canine Atopic Dermatitis Market Analysis and Forecasts, By Product Type

• 6.1. Introduction & Definition
• 6.2. Key Findings / Developments
• 6.3. Market Value Forecast By Product Type, 2020-2035
  • 6.3.1. Glucocorticoids
  • 6.3.2. Immunosuppressants
  • 6.3.3. Monoclonal Antibodies
  • 6.3.4. Calcineurin Inhibitors
  • 6.3.5. Janus kinase (JAK) Inhibitor
  • 6.3.6. Others
• 6.4. Market Attractiveness By Product Type

7. Global Canine Atopic Dermatitis Market Analysis and Forecasts, By Route of Administration

• 7.1. Introduction & Definition
• 7.2. Key Findings / Developments
• 7.3. Market Value Forecast By Route of Administration, 2020-2035
  • 7.3.1. Topical
  • 7.3.2. Oral
  • 7.3.3. Injectable
• 7.4. Market Attractiveness By Route of Administration

8. Global Canine Atopic Dermatitis Market Analysis and Forecasts, By Distribution Channel

• 8.1. Introduction & Definition
• 8.2. Key Findings / Developments
• 8.3. Market Value Forecast By Distribution Channel, 2020-2035
  • 8.3.1. Veterinary Hospitals and Clinics
  • 8.3.2. Veterinary Pharmacies & Drug Stores
  • 8.3.3. E-commerce
  • 8.3.4. Others
• 8.4. Market Attractiveness By Distribution Channel

9. Global Canine Atopic Dermatitis Market Analysis and Forecasts, By Region

• 9.1. Key Findings
• 9.2. Market Value Forecast By Region
  • 9.2.1. North America
  • 9.2.2. Europe
  • 9.2.3. Asia Pacific
  • 9.2.4. Latin America
  • 9.2.5. Middle East & Africa
• 9.3. Market Attractiveness By Country/Region

10. North America Canine Atopic Dermatitis Market Analysis and Forecast

• 10.1. Introduction
  • 10.1.1. Key Findings
• 10.2. Market Value Forecast By Product Type, 2020-2035
  • 10.2.1. Glucocorticoids
  • 10.2.2. Immunosuppressants
  • 10.2.3. Monoclonal Antibodies
  • 10.2.4. Calcineurin Inhibitors
  • 10.2.5. Janus kinase (JAK) Inhibitor
  • 10.2.6. Others
• 10.3. Market Value Forecast By Route of Administration, 2020-2035
  • 10.3.1. Topical
  • 10.3.2. Oral
  • 10.3.3. Injectable
• 10.4. Market Value Forecast By Distribution Channel, 2020-2035
  • 10.4.1. Veterinary Hospitals and Clinics
  • 10.4.2. Veterinary Pharmacies & Drug Stores
  • 10.4.3. E-commerce
  • 10.4.4. Others
• 10.5. Market Value Forecast By Country, 2020-2035
  • 10.5.1. U.S.
  • 10.5.2. Canada
• 10.6. Market Attractiveness Analysis
  • 10.6.1. By Product Type
  • 10.6.2. By Route of Administration
  • 10.6.3. By Distribution Channel
  • 10.6.4. By Country

11. Europe Canine Atopic Dermatitis Market Analysis and Forecast

• 11.1. Introduction
  • 11.1.1. Key Findings
• 11.2. Market Value Forecast By Product Type, 2020-2035
  • 11.2.1. Glucocorticoids
  • 11.2.2. Immunosuppressants
  • 11.2.3. Monoclonal Antibodies
  • 11.2.4. Calcineurin Inhibitors
  • 11.2.5. Janus kinase (JAK) Inhibitor
  • 11.2.6. Others
• 11.3. Market Value Forecast By Route of Administration, 2020-2035
  • 11.3.1. Topical
  • 11.3.2. Oral
  • 11.3.3. Injectable
• 11.4. Market Value Forecast By Distribution Channel, 2020-2035
  • 11.4.1. Veterinary Hospitals and Clinics
  • 11.4.2. Veterinary Pharmacies & Drug Stores
  • 11.4.3. E-commerce
  • 11.4.4. Others
• 11.5. Market Value Forecast By Country, 2020-2035
  • 11.5.1. Germany
  • 11.5.2. U.K.
  • 11.5.3. France
  • 11.5.4. Spain
  • 11.5.5. Italy
  • 11.5.6. Rest of Europe
• 11.6. Market Attractiveness Analysis
  • 11.6.1. By Product Type
  • 11.6.2. By Route of Administration
  • 11.6.3. By Distribution Channel
  • 11.6.4. By Country

12. Asia Pacific Canine Atopic Dermatitis Market Analysis and Forecast

• 12.1. Introduction
  • 12.1.1. Key Findings
• 12.2. Market Value Forecast By Product Type, 2020-2035
  • 12.2.1. Glucocorticoids
  • 12.2.2. Immunosuppressants
  • 12.2.3. Monoclonal Antibodies
  • 12.2.4. Calcineurin Inhibitors
  • 12.2.5. Janus kinase (JAK) Inhibitor
  • 12.2.6. Others
• 12.3. Market Value Forecast By Route of Administration, 2020-2035
  • 12.3.1. Topical
  • 12.3.2. Oral
  • 12.3.3. Injectable
• 12.4. Market Value Forecast By Distribution Channel, 2020-2035
  • 12.4.1. Veterinary Hospitals and Clinics
  • 12.4.2. Veterinary Pharmacies & Drug Stores
  • 12.4.3. E-commerce
  • 12.4.4. Others
• 12.5. Market Value Forecast By Country, 2020-2035
  • 12.5.1. China
  • 12.5.2. Japan
  • 12.5.3. India
  • 12.5.4. Australia & New Zealand
  • 12.5.5. Rest of Asia Pacific
• 12.6. Market Attractiveness Analysis
  • 12.6.1. By Product Type
  • 12.6.2. By Route of Administration
  • 12.6.3. By Distribution Channel
  • 12.6.4. By Country

13. Latin America Canine Atopic Dermatitis Market Analysis and Forecast

• 13.1. Introduction
  • 13.1.1. Key Findings
• 13.2. Market Value Forecast By Product Type, 2020-2035
  • 13.2.1. Glucocorticoids
  • 13.2.2. Immunosuppressants
  • 13.2.3. Monoclonal Antibodies
  • 13.2.4. Calcineurin Inhibitors
  • 13.2.5. Janus kinase (JAK) Inhibitor
  • 13.2.6. Others
• 13.3. Market Value Forecast By Route of Administration, 2020-2035
  • 13.3.1. Topical
  • 13.3.2. Oral
  • 13.3.3. Injectable
• 13.4. Market Value Forecast By Distribution Channel, 2020-2035
  • 13.4.1. Veterinary Hospitals and Clinics
  • 13.4.2. Veterinary Pharmacies & Drug Stores
  • 13.4.3. E-commerce
  • 13.4.4. Others
• 13.5. Market Value Forecast By Country, 2020-2035
  • 13.5.1. Brazil
  • 13.5.2. Mexico
  • 13.5.3. Argentina
  • 13.5.4. Chile
  • 13.5.5. Peru
  • 13.5.6. Colombia
  • 13.5.7. Rest of Latin America
• 13.6. Market Attractiveness Analysis
  • 13.6.1. By Product Type
  • 13.6.2. By Route of Administration
  • 13.6.3. By Distribution Channel
  • 13.6.4. By Country

14. Middle East & Africa Canine Atopic Dermatitis Market Analysis and Forecast

• 14.1. Introduction
  • 14.1.1. Key Findings
• 14.2. Market Value Forecast By Product Type, 2020-2035
  • 14.2.1. Glucocorticoids
  • 14.2.2. Immunosuppressants
  • 14.2.3. Monoclonal Antibodies
  • 14.2.4. Calcineurin Inhibitors
  • 14.2.5. Janus kinase (JAK) Inhibitor
  • 14.2.6. Others
• 14.3. Market Value Forecast By Route of Administration, 2020-2035
  • 14.3.1. Topical
  • 14.3.2. Oral
  • 14.3.3. Injectable
• 14.4. Market Value Forecast By Distribution Channel, 2020-2035
  • 14.4.1. Veterinary Hospitals and Clinics
  • 14.4.2. Veterinary Pharmacies & Drug Stores
  • 14.4.3. E-commerce
  • 14.4.4. Others
• 14.5. Market Value Forecast By Country, 2020-2035
  • 14.5.1. GCC Countries
  • 14.5.2. South Africa
  • 14.5.3. Rest of Middle East & Africa
• 14.6. Market Attractiveness Analysis
  • 14.6.1. By Product Type
  • 14.6.2. By Route of Administration
  • 14.6.3. By Distribution Channel
  • 14.6.4. By Country

15. Competitive Landscape

• 15.1. Market Player - Competition Matrix (By Tier and Size of companies)
• 15.2. Market Share Analysis, by Company (2024)
• 15.3. Company Profiles
  • 15.3.1. Zoetis
    • 15.3.1.1. Company Overview
    • 15.3.1.2. Financial Overview
    • 15.3.1.3. Product Portfolio
    • 15.3.1.4. Business Strategies
    • 15.3.1.5. Recent Developments
  • 15.3.2. Merck & Co., Inc.
    • 15.3.2.1. Company Overview
    • 15.3.2.2. Financial Overview
    • 15.3.2.3. Product Portfolio
    • 15.3.2.4. Business Strategies
    • 15.3.2.5. Recent Developments
  • 15.3.3. Elanco or its affiliates.
    • 15.3.3.1. Company Overview
    • 15.3.3.2. Financial Overview
    • 15.3.3.3. Product Portfolio
    • 15.3.3.4. Business Strategies
    • 15.3.3.5. Recent Developments
  • 15.3.4. Boehringer Ingelheim International GmbH
    • 15.3.4.1. Company Overview
    • 15.3.4.2. Financial Overview
    • 15.3.4.3. Product Portfolio
    • 15.3.4.4. Business Strategies
    • 15.3.4.5. Recent Developments
  • 15.3.5. Virbac Corporation
    • 15.3.5.1. Company Overview
    • 15.3.5.2. Financial Overview
    • 15.3.5.3. Product Portfolio
    • 15.3.5.4. Business Strategies
    • 15.3.5.5. Recent Developments
  • 15.3.6. Vetoquinol
    • 15.3.6.1. Company Overview
    • 15.3.6.2. Financial Overview
    • 15.3.6.3. Product Portfolio
    • 15.3.6.4. Business Strategies
    • 15.3.6.5. Recent Developments
  • 15.3.7. TORAY INDUSTRIES, INC.
    • 15.3.7.1. Company Overview
    • 15.3.7.2. Financial Overview
    • 15.3.7.3. Product Portfolio
    • 15.3.7.4. Business Strategies
    • 15.3.7.5. Recent Developments
  • 15.3.8. Biocelix
    • 15.3.8.1. Company Overview
    • 15.3.8.2. Financial Overview
    • 15.3.8.3. Product Portfolio
    • 15.3.8.4. Business Strategies
    • 15.3.8.5. Recent Developments
  • 15.3.9. Dechra Pharmaceuticals PLC
    • 15.3.9.1. Company Overview
    • 15.3.9.2. Financial Overview
    • 15.3.9.3. Product Portfolio
    • 15.3.9.4. Business Strategies
    • 15.3.9.5. Recent Developments
  • 15.3.10. Bioiberica S.A.U
    • 15.3.10.1. Company Overview
    • 15.3.10.2. Financial Overview
    • 15.3.10.3. Product Portfolio
    • 15.3.10.4. Business Strategies
    • 15.3.10.5. Recent Developments
  • 15.3.11. Ceva
    • 15.3.11.1. Company Overview
    • 15.3.11.2. Financial Overview
    • 15.3.11.3. Product Portfolio
    • 15.3.11.4. Business Strategies
    • 15.3.11.5. Recent Developments
  • 15.3.12. Bimeda Corporate
    • 15.3.12.1. Company Overview
    • 15.3.12.2. Financial Overview
    • 15.3.12.3. Product Portfolio
    • 15.3.12.4. Business Strategies
    • 15.3.12.5. Recent Developments
  • 15.3.13. Other prominent players
    • 15.3.13.1. Company Overview
    • 15.3.13.2. Financial Overview
    • 15.3.13.3. Product Portfolio
    • 15.3.13.4. Business Strategies
    • 15.3.13.5. Recent Developments